论文部分内容阅读
[目的]了解术前脱氧氟尿苷口服化疗对胃癌组织血小板衍化内皮细胞生长因子(PD-ECGF)表达的影响及意义。[方法]胃癌患者术前随机分为三组:组1:氟铁龙800mg/d～1200mg/d,3～5天;组2:5-Fu0.5+CF200mg/d静脉滴注,3～5天;组3:对照组。化疗结束后第1～2天行手术。切除标本采用免疫组化法及TUNEL法检测胃癌组织中PD-ECGF表达率及细胞凋亡指数(AI)。[结果]全组PD-ECGF阳性率为51.9%。PD-ECGF表达率与根治切除、肿瘤侵犯深度、淋巴结转移、有无远处转移及UICC分期无关(P>0.05)。组1中PD-ECGF表达率(28.6%,4/18)明显低于组2(56.3%,9/16)及对照组(65.0%,13/20)(P=0.023)。AI在组1为14.39±9.49,组2为14.11±9.68,明显高于对照组(6.88±7.37)。在PD-ECGF阳性组中肿瘤细胞凋亡指数(8.12±5.19)明显低于阴性组(14.69±11.23),差异有显著性(F=7.409,P=0.009)。随访截止至2006年12月31日,50例获得随访,总的1、2、3、5年生存率分别为78.0%、58.8%、48.7%、48.7%。PD-ECGF阳性患者1、2、3、5年生存率分别为76.0%、56.0%、47.7%、47.7%;低于阴性组的80.0%、60.0%、52.0%、52.0%,但差异无显著性(χ2=0.177,P=0.674)。[结论]术前脱氧氟尿苷口服化疗可降低胃癌组织中PD-ECGF表达率。PD-ECGF阳性表达患者的肿瘤细胞凋亡指数低于阴性组,倾向预后不良。
[Objective] To investigate the effect of preoperative deoxyfluorouridine oral chemotherapy on the expression of platelet-derived endothelial cell growth factor (PD-ECGF) in gastric cancer and its significance. [Methods] Patients with gastric cancer were randomly divided into three groups: group 1: fluticasone 800 mg / d ~ 1200 mg / d for 3 ~ 5 days; group 2: 5-Fu 0.5 + CF 200 mg / 5 days; group 3: control group. 1 to 2 days after the end of chemotherapy surgery. The specimens were excised to detect the expression of PD-ECGF and the apoptosis index (AI) in gastric cancer by immunohistochemistry and TUNEL. [Results] The positive rate of PD-ECGF in the whole group was 51.9%. The expression of PD-ECGF was not associated with radical resection, tumor invasion depth, lymph node metastasis, distant metastasis and UICC stage (P> 0.05). The expression of PD-ECGF in group 1 (28.6%, 4/18) was significantly lower than that in group 2 (56.3%, 9/16) and control group (65.0%, 13/20) (P = 0.023). AI was 14.39 ± 9.49 in group 1, 14.11 ± 9.68 in group 2, significantly higher than that in control group (6.88 ± 7.37). The apoptotic index (8.12 ± 5.19) in PD-ECGF positive group was significantly lower than that in negative group (14.69 ± 11.23), the difference was significant (F = 7.409, P = 0.009). Fifty patients were followed up from December 31, 2006 to December 31, 2006. The overall 1, 2, 3, 5-year survival rates were 78.0%, 58.8%, 48.7% and 48.7%, respectively. The 1, 2, 3, 5-year survival rates of PD-ECGF-positive patients were 76.0%, 56.0%, 47.7% and 47.7%, respectively, which were lower than 80.0%, 60.0%, 52.0% and 52.0% (Χ2 = 0.177, P = 0.674). [Conclusion] Preoperative chemotherapy with deoxyfluorouridine can decrease the expression of PD-ECGF in gastric cancer. The apoptosis index of patients with PD-ECGF positive expression was lower than that of negative group, and the prognosis was poor.